FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis

Author： Baumruker Thomas   Billich Andreas   Brinkmann Volker  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.16, Iss.3, 2007-03, pp. : 283-289

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness

By Clegg A.   Bryant J.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 4, 2001-04 ,pp. : 623-639

Informa Healthcare

Access to resources Recommend Favorite

Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis

By  

Current Pharmaceutical Design, Vol. 17, Iss. 10, 2011-04 ,pp. : 1025-1035

Bentham Science Publishers

Access to resources Recommend Favorite

FTY 720: effective immunosuppression in transplantation

By  

Inpharma, Vol. 1, Iss. 1411, 2003-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation

By Brinkmann V.V.   Pinschewer D.D.   Chiba K.K.   Feng L.L.  

Trends in Pharmacological Sciences, Vol. 21, Iss. 2, 2000-02 ,pp. : 49-52

Elsevier

Access to resources Recommend Favorite

Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

By Ziemssen T.  

Drug Safety, Vol. 24, Iss. 13, 2001-01 ,pp. : 979-990

Adis International

Access to resources Recommend Favorite